Search Results | Blood | American Society of Hematology

1-20 of 719

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Approximating International Myeloma Working Group Uniform Response Criteria to Derive Response for Multiple Myeloma (MM) Patients Using Data from Electronic Health Records (EHR)

Rebekah B. Foster, BA, Max Tromanhauser, BSE, Christopher Gayer, PhD, Patrick K. Gonzales, MS, Kathleen Maignan, NP, Adomah S. Opong, ANP, Aracelis Z. Torres, MPH, PhD, Kenneth R. Carson, MD PhD

Blood (2019) 134 (Supplement_1): 4727.

DOI: https://doi.org/10.1182/blood-2019-127181

Published: 2019

Journal Articles

The Utilization of Screening Tests for Plasma Cell Dyscrasias By Internal Medicine Physicians at a Teaching Hospital

Omar Abughanimeh, MD, Ahmad Al-Shyoukh, Anahat Kaur, MD, Diala Alawneh, Soheila Hamidpour, Anuj Shrestha, MD, Sheshadri Madhusudhana, MD

Blood (2019) 134 (Supplement_1): 4732.

DOI: https://doi.org/10.1182/blood-2019-123077

Published: 2019

Journal Articles

Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?

Blood (2019) 134 (Supplement_1): 1532.

DOI: https://doi.org/10.1182/blood-2019-131442

Published: 2019

Journal Articles

A New Cytokine-Based Stratification Is Highly Predictive of Survivals in AML Patients

Blood (2019) 134 (Supplement_1): 1412.

DOI: https://doi.org/10.1182/blood-2019-125774

Published: 2019

Journal Articles

Survival Outcomes in Patients with Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma According to MYD88 Mutation Status

Agrima Mian, MBBS, MD, Albert Aboseif, DO, Wei Wei, MS, Rajshekhar Chakraborty, MD, Jack Khouri, MD, Joslyn Rudoni, PharmD, Allison M. Winter, MD, Sonam Patel, MD, Deepa Jagadeesh, MDMPH, Robert M. Dean, MD, Brad Pohlman, MD, Stephanie Berg, DO, James R. Cook, MD PhD, Brian T. Hill, MD, Alex V. Mejia Garcia, MD

Blood (2019) 134 (Supplement_1): 5248.

DOI: https://doi.org/10.1182/blood-2019-130396

Published: 2019

Journal Articles

Whole Body Diffusion Weighted MRI (WB DWI) for the Management of Multiple Myeloma: High Concordance between MRI Diffuse Pattern and BONE Marrow Plasma CELL Infiltration RATE

Silvia Mangiacavalli, Zacchino Michela, MD, Virginia Valeria Ferretti, Claudio Salvatore Cartia, MD, Giovanni Savietto, MD, Pietro Benvenuti, MD, Marzia Varettoni, Sara Rattotti, Brociner Marco, Gabriele Merati, MD, Luca Arcaini

Blood (2019) 134 (Supplement_1): 5495.

DOI: https://doi.org/10.1182/blood-2019-126422

Published: 2019

Journal Articles

Prevalence of Monoclonal Gammopathy of Undetermined Significance in a Large Population with Annual Physical Examination in Beijing, China

Jinuo Wang, MD, Jian-Hua Han, Yue-lun Zhang, Xin-xin Cao, Dao-Bin Zhou, Teng-da Xu, Wei Su, Jian Li, MD

Blood (2019) 134 (Supplement_1): 5519.

DOI: https://doi.org/10.1182/blood-2019-124715

Published: 2019

Journal Articles

Phase I/II Study of Carfilzomib, Ruxolitinib and Low-Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma (CarJak)

Shebli Atrash, MD, Myra Robinson, MS, Manisha Bhutani, MD, Jeffrey A. Zonder, Reed Friend, MD, Barry Paul, MD, Daniel Auclair, Jordan Robinsons, Ami P Ndiaye, NP, Kelly Bumgarner, Sarah Norek, James T. Symanowski, PhD, Peter M. Voorhees, MD, Saad Z. Usmani, MDMBBS

Blood (2019) 134 (Supplement_1): 5570.

DOI: https://doi.org/10.1182/blood-2019-130290

Published: 2019

Journal Articles

Clinically Suspected Cast Nephropathy: A Retrospective, Multi-Center, Real-World Study

Agoston Gyula Szabo, MD, Jonathan Thorsen, MD PhD, Charlotte Toftmann Hansen, MD PhD, Maja Ølholm Vase, MD PhD, Manuela Teodorescu, MD, Simon Bo Pedersen, MD, Simon Bertram Flæng, MD, Ulf Christian Frølund, MD, Annette Juul Vangsted, MD PhD, Torben Plesner, MD DSc

Blood (2019) 134 (Supplement_1): 5553.

DOI: https://doi.org/10.1182/blood-2019-124336

Published: 2019

Journal Articles

Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)

Deepu Madduri, MD, Saad Z. Usmani, MD, Sundar Jagannath, Indrajeet Singh, PhD, Enrique Zudaire, PhD, Tzu-Min Yeh, Alicia J. Allred, PhD, Arnob Banerjee, MD, Jenna D. Goldberg, MD, Jordan M Schecter, MD, Sen Zhuang, Jeffrey R. Infante, MD, Syed Rizvi, Xiaohu (Frank) Fan, MD PhD, Andrzej Jakubowiak, MD PhD, Jesus G. Berdeja, MD

Blood (2019) 134 (Supplement_1): 577.

DOI: https://doi.org/10.1182/blood-2019-121731

Published: 2019

Journal Articles

Integrative Analysis of Baseline Prognostic Features and Achievement of Minimal Residual Disease Negativity As Predictors of Early Relapse in Transplant-Eligible Multiple Myeloma Patients

Blood (2019) 134 (Supplement_1): 605.

DOI: https://doi.org/10.1182/blood-2019-125588

Published: 2019

Journal Articles

A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: First Report of Efficacy and Safety

Blood (2019) 134 (Supplement_1): 1898.

DOI: https://doi.org/10.1182/blood-2019-129103

Published: 2019

Journal Articles

Identification of Clonal Immunoglobulin λ Light-Chain Gene Rearrangements in AL Amyloidosis Using Next Generation Sequencing

Blood (2019) 134 (Supplement_1): 1748.

DOI: https://doi.org/10.1182/blood-2019-125028

Published: 2019

Journal Articles

Pulmonary Function Tests Reveal Unrecognized Lung Dysfunction and Have Independent Prognostic Significance in Patients with Systemic AL Amyloidosis

Eftathios Kastritis, Georgia Trakada, MD, Despina Fotiou, BMBS, MA, Magdalini Migkou, MD, Maria Gavriatopoulou, MD, Nikolaos Kanellias, MD, Evangelos Eleutherakis-Papaiakovou, MD, Ioanna Dialoupi, MD, Ioannis Ntanasis-Stathopoulos, MD, Despina Mparmparousi, Aikaterini Xirokosta, Evangelos Terpos, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1842.

DOI: https://doi.org/10.1182/blood-2019-125877

Published: 2019

Journal Articles

The Quest for Indicators of Profound Hematologic Response in AL Amyloidosis: Complete Response Remains the Optimal Goal of Therapy

Paolo Milani, MD PhD, Marco Basset, MD, Andrea Foli, MD, Mario Nuvolone, MD PhD, Jessica Ripepi, Margherita Bozzola, Giampaolo Merlini, MD, Giovanni Palladini, MD PhD

Blood (2019) 134 (Supplement_1): 1901.

DOI: https://doi.org/10.1182/blood-2019-130378

Published: 2019

Journal Articles

Overall and Progression Free Survival from the Mcrn-003/Myx.1 Trial: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma

Christopher P Venner, MD, Richard Leblanc, MDFRCPC, Irwindeep Sandhu, MDFRCPC, Darrell J White, MD, Andrew Belch, MD, Donna E Reece, MD, Christine I Chen, MD, Sean Dolan, MD, Marc Lalancette, MD FRCP, Martha L Louzada, MDMSc, Andrea Kew, MDFRCP(C), Arleigh McCurdy, MD, Tony Reiman, MD, Max Sherry, Gail T. McDonald, Bethany Elaine Monteith, MD, Engin Gul, BS, MBA, Bingshu E. Chen, Annette E. Hay

Blood (2019) 134 (Supplement_1): 1871.

DOI: https://doi.org/10.1182/blood-2019-122637

Published: 2019

Journal Articles

High Throughput Drug Synergy Testing in a Clinical Trial of Panobinostat, Carfilzomib, Dexamethasone to Define Response Biomarkers for Relapsed/Refractory Multiple Myeloma

Pamela S. Becker, MD PhD, Kim Quach, Ted A Gooley, PhD, Edward N. Libby, III, MD, Andrew J. Cowan, MD, David G. Coffey, MD, Bret Gary Degraaff, BS, Cody Hammer, Jin Dai, PhD, Sylvia Chien, Josh Epworth, ARNP, Gabrielle A Zecha, PA-C, Heather Smith, PA-C, Timothy S Martins, PhD

Blood (2019) 134 (Supplement_1): 1902.

DOI: https://doi.org/10.1182/blood-2019-130990

Published: 2019

Journal Articles

Baseline and Increases in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Relapsed/Refractory Multiple Myeloma Patients Undergoing New Treatments

Sean Bujarski, BA, Kyle Udd, BA, Camilia Soof, BS, Tanya M. Spektor, PhD, Tahmineh Safaie, Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Joshua Stern, Cathy S. Wang, BS, Ning Xu, PhD, Marsiye Emamy-Sadr, Regina Swift, Ashkon Rahbari, Saurabh Patil, BS, Eric Souther, James R. Berenson, MD

Blood (2019) 134 (Supplement_1): 1786.

DOI: https://doi.org/10.1182/blood-2019-132012

Published: 2019

Journal Articles

Serum Neutrophil Gelatinase-Associated Lipocalin Independently Predicts for Renal Response in Myeloma Patients with Severe Renal Impairment

Meletios A. Dimopoulos, MD, Maria Roussou, MD, Eftathios Kastritis, Alexandra Margeli, PhD, Evangelos Eleutherakis-Papaiakovou, MD, Ioannis Ntanasis-Stathopoulos, MD, Nikolaos Kanellias, MD, Gerasimos-Petros Papassotiriou, PhD, Despina Fotiou, MD, Magdalini Migkou, MD, Maria Gavriatopoulou, MD, Erasmia Psimenou, MD, Ioannis Papassotiriou, PhD, Evangelos Terpos, MD PhD

Blood (2019) 134 (Supplement_1): 1877.

DOI: https://doi.org/10.1182/blood-2019-123912

Published: 2019

Journal Articles

Using Current Clinical Markers to Define High Risk Smoldering Multiple Myeloma: Agree to Disagree

Elizabeth Hill, MD, Neha Korde, MD, Sham Mailankody, MBBS, Candis Morrison, CNP, PhD, Alexander Dew, DO, Jennifer Hsu Albert, RN, Katherine Graap, RN, Francesco Maura, MD, Ola Landgren, MD PhD, Dickran Kazandjian, MD

Blood (2019) 134 (Supplement_1): 1794.

DOI: https://doi.org/10.1182/blood-2019-126952

Published: 2019

2 3 4 5

NARROW

Approximating International Myeloma Working Group Uniform Response Criteria to Derive Response for Multiple Myeloma (MM) Patients Using Data from Electronic Health Records (EHR)

The Utilization of Screening Tests for Plasma Cell Dyscrasias By Internal Medicine Physicians at a Teaching Hospital

Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?

A New Cytokine-Based Stratification Is Highly Predictive of Survivals in AML Patients

Survival Outcomes in Patients with Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma According to MYD88 Mutation Status

Whole Body Diffusion Weighted MRI (WB DWI) for the Management of Multiple Myeloma: High Concordance between MRI Diffuse Pattern and BONE Marrow Plasma CELL Infiltration RATE

Prevalence of Monoclonal Gammopathy of Undetermined Significance in a Large Population with Annual Physical Examination in Beijing, China

Phase I/II Study of Carfilzomib, Ruxolitinib and Low-Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma (CarJak)

Clinically Suspected Cast Nephropathy: A Retrospective, Multi-Center, Real-World Study

Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)

Integrative Analysis of Baseline Prognostic Features and Achievement of Minimal Residual Disease Negativity As Predictors of Early Relapse in Transplant-Eligible Multiple Myeloma Patients

A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: First Report of Efficacy and Safety

Identification of Clonal Immunoglobulin λ Light-Chain Gene Rearrangements in AL Amyloidosis Using Next Generation Sequencing

Pulmonary Function Tests Reveal Unrecognized Lung Dysfunction and Have Independent Prognostic Significance in Patients with Systemic AL Amyloidosis

The Quest for Indicators of Profound Hematologic Response in AL Amyloidosis: Complete Response Remains the Optimal Goal of Therapy

Overall and Progression Free Survival from the Mcrn-003/Myx.1 Trial: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma

High Throughput Drug Synergy Testing in a Clinical Trial of Panobinostat, Carfilzomib, Dexamethasone to Define Response Biomarkers for Relapsed/Refractory Multiple Myeloma

Baseline and Increases in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Relapsed/Refractory Multiple Myeloma Patients Undergoing New Treatments

Serum Neutrophil Gelatinase-Associated Lipocalin Independently Predicts for Renal Response in Myeloma Patients with Severe Renal Impairment

Using Current Clinical Markers to Define High Risk Smoldering Multiple Myeloma: Agree to Disagree

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only